Second Sight Medical Products (NASDAQ:EYES) received a $5.00 price target from investment analysts at HC Wainwright in a note issued to investors on Thursday. The firm presently has a “buy” rating on the medical device company’s stock. HC Wainwright’s price objective points to a potential upside of 224.68% from the company’s previous close.
EYES has been the subject of a number of other reports. Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. ValuEngine raised shares of Second Sight Medical Products from a “hold” rating to a “buy” rating in a research report on Friday, November 2nd.
Shares of NASDAQ EYES traded down $0.08 during mid-day trading on Thursday, reaching $1.54. The company had a trading volume of 684,094 shares, compared to its average volume of 175,057. The firm has a market capitalization of $114.03 million, a price-to-earnings ratio of -2.61 and a beta of 2.91. Second Sight Medical Products has a 12-month low of $1.13 and a 12-month high of $2.58.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Wednesday, November 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $2.25 million during the quarter, compared to analyst estimates of $2.48 million. Second Sight Medical Products had a negative net margin of 408.41% and a negative return on equity of 582.43%. As a group, equities research analysts predict that Second Sight Medical Products will post -0.58 EPS for the current fiscal year.
In other news, Director Gregg Williams acquired 17,052 shares of the company’s stock in a transaction that occurred on Thursday, August 23rd. The shares were purchased at an average price of $1.63 per share, for a total transaction of $27,794.76. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders purchased 6,105,967 shares of company stock worth $9,706,383 and sold 23,777 shares worth $41,543. Corporate insiders own 34.70% of the company’s stock.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.